Register Today Menu

"On the other hand, we denounce with righteous indignation and dislike men who are so beguiled and demoralized by the charms of pleasure of the moment, so blinded by desire, that they cannot foresee the pain and trouble that are bound to ensue; and equal blame belongs to those who fail in their duty through weakness of will, which is the same as saying through shrinking from toil and pain. These cases are perfectly simple and easy to distinguish. In a free hour, when our power of choice is untrammelled and when nothing prevents our being able to do what we like best, every pleasure is to be welcomed and every pain avoided. But in certain circumstances and owing to the claims of duty or the obligations of business it will frequently occur that pleasures have to be repudiated and annoyances accepted. The wise man therefore always holds in these matters to this principle of selection: he rejects pleasures to secure other greater pleasures, or else he endures pains to avoid worse pains."

"At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt mollitia animi, id est laborum et dolorum fuga. Et harum quidem rerum facilis est et expedita distinctio. Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum necessitatibus saepe eveniet ut et voluptates repudiandae sint et molestiae non recusandae. Itaque earum rerum hic tenetur a sapiente delectus, ut aut reiciendis voluptatibus maiores alias consequatur aut perferendis doloribus asperiores repellat."

Simbec-Orion Clinical Pharmacology will soon be running a two part study to investigate a drug called MB272.

The overall objectives of the study are to determine the safety, tolerability and concentration in the blood of the study drug when evaluated in different conditions i.e., different dose strengths, following administration of single and multiple doses, and following administration in two different forms.

The study also aims to evaluate the effect of the study drug on the body, through the collection of blood samples at different times through the day.

Simbec-Orion Clinical Pharmacology will soon be running a two part study to investigate a drug called MB272.

The overall objectives of the study are to determine the safety, tolerability and concentration in the blood of the study drug when evaluated in different conditions i.e., different dose strengths, following administration of single and multiple doses, and following administration in two different forms.

The study also aims to evaluate the effect of the study drug on the body, through the collection of blood samples at different times through the day.

Simbec-Orion Clinical Pharmacology will soon be running a two part study to investigate a drug called MB272.

The overall objectives of the study are to determine the safety, tolerability and concentration in the blood of the study drug when evaluated in different conditions i.e., different dose strengths, following administration of single and multiple doses, and following administration in two different forms.

The study also aims to evaluate the effect of the study drug on the body, through the collection of blood samples at different times through the day.

"Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?"

"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum."

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

"On the other hand, we denounce with righteous indignation and dislike men who are so beguiled and demoralized by the charms of pleasure of the moment, so blinded by desire, that they cannot foresee the pain and trouble that are bound to ensue; and equal blame belongs to those who fail in their duty through weakness of will, which is the same as saying through shrinking from toil and pain. These cases are perfectly simple and easy to distinguish. In a free hour, when our power of choice is untrammelled and when nothing prevents our being able to do what we like best, every pleasure is to be welcomed and every pain avoided. But in certain circumstances and owing to the claims of duty or the obligations of business it will frequently occur that pleasures have to be repudiated and annoyances accepted. The wise man therefore always holds in these matters to this principle of selection: he rejects pleasures to secure other greater pleasures, or else he endures pains to avoid worse pains."

Posts list

If you are a healthy male or female aged between 18 and 65, then you may be eligible to participate in a study investigating a new drug being developed for the treatment of a skin condition called atopic dermatitis (AD).

Study Payment* £1,925 – £5,300.

Apply for this study

*Terms & Conditions apply.

Study Payment: £1,925 – £5,300

"*" indicates required fields

Step 1 of 3

33%

This field is hidden when viewing the form

Advertising Source

* indicates a required field

By agreeing to this form and selecting the box as outlined on your application, you are confirming that you have read the information provided in our data protection and consent policy, and give your consent for Simbec-Orion to record and retain your personal and special categories of data for the purposes and duration(s) stated above.

Please confirm that you have read these terms and understand that Simbec-Orion will be holding and processing your personal and special categories of data for the purposes stated above.

Simbec-Orion are also required to process your bio-metric data (a photograph only when you attend an onsite screening visit), we do this to ensure we can identify you for security purposes. We do not share this data with any other third-party, we solely use this data for the purpose of recognition. For the completion of your enrolment and part of your eligibility, we are required to collect this data. By selecting the box below, you also explicitly consent to the use of your bio-metric data as and when it is collected.

Agreement*

I understand and wish to proceed

* indicates a required field

Please select the period or part of the study you wish to apply for

Please select the period or part of the study you wish to apply forPart 1: Standard Group – Study payment: £1,925Part 1: Food Effect Group – Study payment: £3,525Part 2 – Study payment: £5,300

Do you have any dietary restrictions which would prevent you from consuming a high-fat meal (including meat, gluten and dairy products)?*

Yes

No

(i.e., vegan/vegetarian, medical, social, cultural or religious)

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this part of the study.

You may be eligible to apply for one of the other parts of this study.

 

Are you currently using some form of contraception?*

Which of the following best describes you or your contraceptive status?VasectomyBarrier Method (male condom only)Post-menopausalHysterectomySexual abstinence (refraining from heterosexual intercourse as the preferred and usual lifestyle choice)None of the above

Unfortunately despite females being able to fall between the age category of 18-65, only females who are meet the following contraceptive status are eligible to participate:
– post-menopausal,
– surgical sterile, or
– sexual abstinent (or willing to be) from heterosexual intercourse.
This is based on the inclusion criteria as outlined in the clinical study protocol.

Unfortunately to participate in a clinical study you must be willing to use a listed contraceptive method prior to being enrolled in the study

Are you registered with a GP*

Yes

No

(must be a UK resident for at least 1 year)?

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to register at this time.

You need to be registered with a GP for at least 3 months in order to participate in a clinical trial. This is to ensure your safety, and your past medical history can be safely evaluated from your GP to assess your suitability for each and every trial.

Have you been diagnosed or tested positive for Coronavirus/COVID-19 within the last month?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply at this time.

Have you received a COVID-19 vaccine or any other type of vaccine within the last 35 days?*

Yes

No

If yes, please give details of vaccine, including the date

Do you suffer from or ever had any other serious illnesses as diagnosed by your GP or health professional?*

Yes

No

(e.g., neurological, endocrinal, cardiovascular, pulmonary, haematological, immunologic, psychiatric, gastrointestinal, renal, hepatic and metabolic disease)

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

Are you taking any prescription or repeat medication from a GP or a chemist*

Yes

No

(including inhalers, over-the-counter medications, and vitamins or supplements)

If yes, please give details*

Do you regularly use illegal drugs?*

Yes

No

(i.e., Substances that are used for non-medicinal and leisure purposes. We test as part of the screening procedures.)

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply at this time.

Have you completed any other studies in the last 30 days?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

Have you ever suffered from a serious allergic reaction or have a known severe allergy?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

Do you smoke or use any nicotine products (including vapes and eCigarettes)?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

Have you smoked or used any nicotine products within the last 6 months?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

Have you donated, given or lost more than 450ml of blood/blood products in the last 30 days?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

Do you drink alcohol?*

Yes

No

Do you consume more than 14 units per week?*

Yes

No

(For example, a can of beer/cider/lager is approximately 2 units)

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

Have you had any body piercings or tattoos in the last 3 months?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

* indicates a required field

Your details

First Name*

Last Name*

Gender at Birth

Please select your gender at birthMaleFemale

Date of Birth*

DayDay12345678910111213141516171819202122232425262728293031

MonthMonth123456789101112

YearYear20262025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980197919781977197619751974197319721971197019691968196719661965196419631962196119601959195819571956195519541953195219511950194919481947194619451944194319421941194019391938193719361935193419331932193119301929192819271926192519241923192219211920

This field is hidden when viewing the form

Age

Height*

Please select your height below4 foot 8 (142cm)4 foot 9 (145cm)4 foot 10 (147cm)4 foot 11 (150cm)5 foot (152cm)5 foot 1 (155cm)5 foot 2 (157cm)5 foot 3 (160cm)5 foot 4 (163cm)5 foot 5 (165cm)5 foot 6 (168cm)5 foot 7 (170cm)5 foot 8 (173cm)5 foot 9 (175cm)5 foot 10 (178cm)5 foot 11 (180cm)6 foot (183cm)6 foot 1 (185cm)6 foot 2 (188cm)6 foot 3 (191cm)6 foot 4 (193cm)6 foot 5 (196cm)6 foot 6 (198cm)6 foot 7 (201cm)6 foot 8 (203cm)6 foot 9 (206cm)6 foot 10 (208cm)6 foot 11 (211cm)7 foot (213cm)

Weight*

Please select your weight below7 stone, 12 lb / 49.90 kg7 stone, 13 lb / 50.35 kg8 stone, 0 lb / 50.80 kg8 stone, 1 lb / 51.26 kg8 stone, 2 lb / 51.71 kg8 stone, 3 lb / 52.16 kg8 stone, 4 lb / 52.62 kg8 stone, 5 lb / 53.07 kg8 stone, 6 lb / 53.52 kg8 stone, 7 lb / 53.98 kg8 stone, 8 lb / 54.43 kg8 stone, 9 lb / 54.88 kg8 stone, 10 lb / 55.34 kg8 stone, 11 lb / 55.79 kg8 stone, 12 lb / 56.25 kg8 stone, 13 lb / 56.70 kg9 stone, 0 lb / 57.15 kg9 stone, 1 lb / 57.61 kg9 stone, 2 lb / 58.06 kg9 stone, 3 lb / 58.51 kg9 stone, 4 lb / 58.97 kg9 stone, 5 lb / 59.42 kg9 stone, 6 lb / 59.87 kg9 stone, 7 lb / 60.33 kg9 stone, 8 lb / 60.78 kg9 stone, 9 lb / 61.23 kg9 stone, 10 lb / 61.69 kg9 stone, 11 lb / 62.14 kg9 stone, 12 lb / 62.60 kg9 stone, 13 lb / 63.05 kg10 stone, 0 lb / 63.50 kg10 stone, 1 lb / 63.96 kg10 stone, 2 lb / 64.41 kg10 stone, 3 lb / 64.86 kg10 stone, 4 lb / 65.32 kg10 stone, 5 lb / 65.77 kg10 stone, 6 lb / 66.22 kg10 stone, 7 lb / 66.68 kg10 stone, 8 lb / 67.13 kg10 stone, 9 lb / 67.59 kg10 stone, 10 lb / 68.04 kg10 stone, 11 lb / 68.49 kg10 stone, 12 lb / 68.95 kg10 stone, 13 lb / 69.40 kg11 stone, 0 lb / 69.85 kg11 stone, 1 lb / 70.31 kg11 stone, 2 lb / 70.76 kg11 stone, 3 lb / 71.21 kg11 stone, 4 lb / 71.67 kg11 stone, 5 lb / 72.12 kg11 stone, 6 lb / 72.57 kg11 stone, 7 lb / 73.03 kg11 stone, 8 lb / 73.48 kg11 stone, 9 lb / 73.94 kg11 stone, 10 lb / 74.39 kg11 stone, 11 lb / 74.84 kg11 stone, 12 lb / 75.30 kg11 stone, 13 lb / 75.75 kg12 stone, 0 lb / 76.20 kg12 stone, 1 lb / 76.66 kg12 stone, 2 lb / 77.11 kg12 stone, 3 lb / 77.56 kg12 stone, 4 lb / 78.02 kg12 stone, 5 lb / 78.47 kg12 stone, 6 lb / 78.93 kg12 stone, 7 lb / 79.38 kg12 stone, 8 lb / 79.83 kg12 stone, 9 lb / 80.29 kg12 stone, 10 lb / 80.74 kg12 stone, 11 lb / 81.19 kg12 stone, 12 lb / 81.65 kg12 stone, 13 lb / 82.10 kg13 stone, 0 lb / 82.55 kg13 stone, 1 lb / 83.01 kg13 stone, 2 lb / 83.46 kg13 stone, 3 lb / 83.91 kg13 stone, 4 lb / 84.37 kg13 stone, 5 lb / 84.82 kg13 stone, 6 lb / 85.28 kg13 stone, 7 lb / 85.73 kg13 stone, 8 lb / 86.18 kg13 stone, 9 lb / 86.64 kg13 stone, 10 lb / 87.09 kg13 stone, 11 lb / 87.54 kg13 stone, 12 lb / 88.00 kg13 stone, 13 lb / 88.45 kg14 stone, 0 lb / 88.90 kg14 stone, 1 lb / 89.36 kg14 stone, 2 lb / 89.81 kg14 stone, 3 lb / 90.26 kg14 stone, 4 lb / 90.72 kg14 stone, 5 lb / 91.17 kg14 stone, 6 lb / 91.63 kg14 stone, 7 lb / 92.08 kg14 stone, 8 lb / 92.53 kg14 stone, 9 lb / 92.99 kg14 stone, 10 lb / 93.44 kg14 stone, 11 lb / 93.89 kg14 stone, 12 lb / 94.35 kg14 stone, 13 lb / 94.80 kg15 stone, 0 lb / 95.25 kg15 stone, 1 lb / 95.71 kg15 stone, 2 lb / 96.16 kg15 stone, 3 lb / 96.62 kg15 stone, 4 lb / 97.07 kg15 stone, 5 lb / 97.52 kg15 stone, 6 lb / 97.98 kg15 stone, 7 lb / 98.43 kg15 stone, 8 lb / 98.88 kg15 stone, 9 lb / 99.34 kg15 stone, 10 lb / 99.79 kg15 stone, 11 lb / 100.24 kg15 stone, 12 lb / 100.70 kg15 stone, 13 lb / 101.15 kg16 stone, 0 lb / 101.60 kg16 stone, 1 lb / 102.06 kg16 stone, 2 lb / 102.51 kg16 stone, 3 lb / 102.97 kg16 stone, 4 lb / 103.42 kg16 stone, 5 lb / 103.87 kg16 stone, 6 lb / 104.33 kg16 stone, 7 lb / 104.77 kg16 stone, 8 lb / 105.23 kg16 stone, 9 lb / 105.68 kg16 stone, 10 lb / 106.14 kg16 stone, 11 lb / 106.59 kg16 stone, 12 lb / 107.04 kg16 stone, 13 lb / 107.5 kg17 stone, 0 lb / 107.95 kg17 stone, 1 lb / 108.4 kg17 stone, 2 lb / 108.86 kg17 stone, 3 lb / 109.31 kg17 stone, 4 lb / 109.76 kg17 stone, 5 lb / 110.22 kg17 stone, 6 lb / 110.67 kg17 stone, 7 lb / 111.13 kg17 stone, 8 lb / 111.58 kg17 stone, 9 lb / 112.03 kg17 stone, 10 lb / 112.49 kg17 stone, 11 lb / 112.94 kg17 stone, 12 lb / 113.39 kg17 stone, 13 lb / 113.85 kg18 stone, 0 lb / 114.3 kg18 stone, 1 lb / 114.75 kg18 stone, 2 lb / 115.21 kg18 stone, 3 lb / 115.66 kg18 stone, 4 lb / 116.11 kg18 stone, 5 lb / 116.57 kg18 stone, 6 lb / 117.02 kg18 stone, 7 lb / 117.48 kg18 stone, 8 lb / 117.93 kg18 stone, 9 lb / 118.38 kg18 stone, 10 lb / 118.84 kg18 stone, 11 lb / 119.29 kg18 stone, 12 lb / 119.74 kg18 stone, 13 lb / 120.2 kg19 stone, 0 lb / 120.65 kg19 stone, 1 lb / 121.1 kg19 stone, 2 lb / 121.56 kg19 stone, 3 lb / 122.01 kg19 stone, 4 lb / 122.46 kg

Your BMI

Your BMI

This field is hidden when viewing the form

BMI Calc

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

Race*

Please select your race belowAmerican Indian or Alaska NativeAsianBlack or African AmericanNative Hawaiian or Other Pacific IslanderWhiteUnknownOther Race (please state below)

Your Race*

Street Address*

City*

Postcode*

Phone Number*

Email*

Can we contact you by email?

Yes

Can we contact you by SMS?

Yes

Can we contact you by phone?

Yes

Please select at least one contact mechanism to facilitate your participation in future clinical studies.

Study Information

Simbec-Orion Clinical Pharmacology will soon be running a three-part study to investigate the study drug, SYX-5219.

The objectives of this study are to determine the safety, tolerability and levels of SYX-5219 in the blood and urine when SYX-5219 is given in different conditions e.g., following administration of different dose strengths, single and multiple doses, in the presence and absence of food and in the intended patient population. As well as evaluating the above, the study will also investigate and explore the effect of SYX-5219 on certain aspects of ECG (electrocardiogram) parameters, and the effect on the levels of cholesterol.

SYX-5219 is being developed as a potential treatment for a condition known as atopic dermatitis (AD); a skin condition often referred to as eczema which causes inflammation, redness and irritation of the skin. Currently, there are limited treatment options available for this condition (particularly for moderate to severe AD) which are considered long term and effective and there are no known cures. Therefore, there is an unmet need to develop potential new treatments which could be more effective.

This study will be split into three separate parts (Part 1, Part 2 and Part 3), and you will only participate in one part of the study (Part 1 and Part 2 for healthy volunteers only).

Ready? Let’s get started

Part 1 Standard Group

The purpose of Part 1 is to evaluate the study objectives when SYX-5219 is administered as a single dose at increasing dose strengths.

Part 1 will consist of up to 8 groups of up to 8 participants: each group will evaluate a different dose of SYX-5219 starting at the lowest dose and gradually increasing in each group. This is known as a single ascending dose (SAD) study. Each group will receive SYX-5219 or a placebo (which contains no active drug) in the form of oral capsule(s) which participants will swallow.

Stay Requirements

If you participate in this part of the study, you will be required to stay at the Simbec-Orion clinical unit for a maximum period of 5 days (4 overnight stays) per treatment period followed by two return visits on Day 5 & Day 6 of each treatment period and a follow-up visit approximately 10 days following the last dose on Day 1.

Visits

You should also note that the timing of certain visits during the study i.e., the return visits on Day 5 & Day 6 and the post-study follow up visit may be extended/modified for all groups, or an additional return visit may be added (apart from Group 1) if the data generated during the study indicates that it is necessary to do so (you will be informed as to whether this is the case and when these visits will take place). Regardless of which group you are participating in, you should ensure that you are able to commit to completing all visits before agreeing to participate in this study and have sufficient flexibility to accommodate any revisions in the return visit/post-study follow up visit schedule.

Study Payment

If you are participating in the standard groups within Part 1 i.e., only completing one treatment period and you complete this part of the study, you will receive a maximum inconvenience payment of £1925.

Screening Visit
Day -35 to Day -2

Treatment Period
Day -1 to 4

Return Visits
Day 5 & Day 6

Post Study Follow Up Visit
Day 11

Apply Now. Be Amazing

Part 1 Food Effect Group

The purpose of Part 1 is to evaluate the study objectives when SYX-5219 is administered as a single dose at increasing dose strengths.

In addition, one group in Part 1 will investigate the effect of food on SYX-5219 by comparing the effects after taking a single dose of SYX-5219 following an overnight fast with the effects when SYX-5219 is given after eating a high fat meal.

Stay Requirements

If you participate in this part of the study and are in the food effect group i.e., completing two treatment periods, you will be required to stay at the Simbec-Orion clinical unit for a maximum period of 5 days (4 overnight stays) per treatment period followed by two return visits on Day 5 & Day 6 of each treatment period and a follow-up visit approximately 10 days following the last dose on Day 1 of treatment period 2. Each dose in each treatment period will be separated by a minimum period of 10 days; however, this period may be longer so you will be informed during the course of the study as to whether you are participating in this group and in addition, when you will need to return to complete the second treatment period.

Visits

You should also note that the timing of certain visits during the study i.e., the return visits on Day 5 & Day 6 and the post-study follow up visit may be extended/modified for all groups, or an additional return visit may be added (apart from Group 1) if the data generated during the study indicates that it is necessary to do so (you will be informed as to whether this is the case and when these visits will take place). Regardless of which group you are participating in, you should ensure that you are able to commit to completing all visits before agreeing to participate in this study and have sufficient flexibility to accommodate any revisions in the return visit/post-study follow up visit schedule.

Study Payment

If you are in the food effect group i.e., completing two treatment periods and you complete this part of the study, you will receive a maximum inconvenience payment of £3525.

Screening Visit
Day -35 to Day -2

Treatment Period 1
Day -1 to 4

Return Visits
Day 5 & Day 6

Washout Period
minimum of 10 days

Treatment Period 2
Day -1 to 4

Return Visits
Day 5 & Day 6

Post Study Follow Up Visit
Day 11

Apply Now. Be Amazing

Part 2

The purpose of Part 2 is to evaluate the study objectives when SYX-5219 is administered as multiple doses (currently planned as once daily) for a period of up to 14 days at increasing dose strengths.

Part 2 will consist of up to 5 planned groups of up to 8 participants: each group will evaluate a different dose of SYX-5219 based upon doses which have been evaluated in Part 1 of the study (where single doses at different dose strengths were given). This is known as a multiple ascending dose (MAD) study. Each group will receive SYX-5219 or a placebo (which contains no active drug) in the form of oral capsule(s) which participants will swallow

Stay Requirements

If you participate in this part of the study, you will be required to stay at the Simbec-Orion clinical unit for a maximum period of 17 days (16 overnight stays) followed by two return visits on Day 18 & Day 19 and a post study follow-up visit approximately 14 days following the last dose of SYX-5219 on Day 28.

Visits

You should also note that the timing of certain visits during the study i.e., the return visits on Day 18 & Day 19 and the post-study follow up visit may be extended/modified for all groups, or an additional return visit may be added if the data generated during the study indicates that it is necessary to do so (you will be informed as to whether this is the case and subsequently when these visits will take place). Therefore, you should ensure that you are able to commit to completing all visits before agreeing to participate in this study and have sufficient flexibility to accommodate any revisions in the return visit/post-study follow up visit schedule.

Study Payment

If you complete this part of the study, you will receive a maximum inconvenience payment of £5300.

Screening Visit
Day -35 to Day -2

Treatment Period
Days -1 to 16

Return Visits
Day 18 & Day 19

Post Study Follow Up Visit
Day 28

Apply Now. Be Amazing

1914 translation by H. Rackham

06/12/2023

“On the other hand, we denounce with righteous indignation and dislike men who are so beguiled and demoralized by the charms of pleasure of the moment, so blinded by desire, that they cannot foresee the pain and trouble that are bound to ensue; and equal blame belongs to those who fail in their duty through […]

Read

Section 1.10.33 of “de Finibus Bonorum et Malorum”, written by Cicero in 45 BC

06/12/2023

“At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt mollitia animi, id est laborum et dolorum fuga. Et harum quidem rerum facilis est et expedita distinctio. Nam libero tempore, […]

Read

News item from Simbec-Orion

06/12/2023

Simbec-Orion Clinical Pharmacology will soon be running a two part study to investigate a drug called MB272. The overall objectives of the study are to determine the safety, tolerability and concentration in the blood of the study drug when evaluated in different conditions i.e., different dose strengths, following administration of single and multiple doses, and […]

Read

Section 1.10.32 of “de Finibus Bonorum et Malorum”, written by Cicero in 45 BC

06/12/2023

“Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque […]

Read

The standard Lorem Ipsum passage, used since the 1500s

06/12/2023

“Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat […]

Read

What is Lorem Ipsum?

05/12/2023

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into […]

Read